Vienna-based Biotech company PhagoMed Biopharma was awarded the Austrian Entrepreneurship Award ‘Phönix 2018’ in the category “Start-Up International”.
The award was presented jointly by the Austrian Minister of Digital and Economic Affairs and the Austrian Minister of Education, Science and Research during a prize ceremony in Vienna. The Phoenix award honours the development of antibiotics alternatives based on phages, a class of natural viruses that only infect bacteria, at the Vienna Biocenter.
PhagoMed Biopharma is a biotech company focused on the development of human therapeutic applications of phage therapy. Its development programs are based on the last-resort treatment experiences of its clinical co-founders with phages as well as research collaborations with highly prestigious scientists and research institutions in Germany and Belgium. Phages therefore have the potential to become a highly effective alternative to antibiotics for the treatment of multi-drug resistant infections. PhagoMed’s clinical co-founders have successfully treated individual patients with phages as a last resort when antibiotics had failed.
Since its incorporation in November 2017, the company has raised more than €4 million in public grants and private investments. PhagoMed’s office and laboratories are based at the Vienna Biocenter (Vienna, Austria)
The high potential of PhagoMed technology as well as the high socio-political relevance of its development programs were recognized by the distinguished jury of the Austrian Entrepreneurship Award.